MYLAN HAS FIRST GENERIC VERSION OF BOEHRINGER-INGELHEIM's COMBIPRES
Executive Summary
MYLAN HAS FIRST GENERIC VERSION OF BOEHRINGER-INGELHEIM's COMBIPRES (clonidine/chlorthalidone); the generic company began marketing the combination product during the week following ANDA approval of the drug on Feb. 9. Mylan estimated the current market for the brandname drug at approximately $17-18 mil. annually, based on IMS data. Mylan is marketing the generic at an average wholesale price of $23.35 for 100 capsules of .1 mg clonidine/15 mg chlorthalidone; $31.20 for 100 capsules of .2 mg clonidine/15 mg chlorthalidone; and $37.70 for 100 capsules of .3 mg clonidine/15 mg chlorthalidone. Generic versions of clonidine (Boehringer-Ingelheim's Catapres) have been available since July 1986, when the patent on Catapres expired. Mylan indicated that it has plans to market generic clonidine as well. In 1986, Mylan received first generic approvals for five products. Of those, the firm received a same day approval for haloperidol with Searle (June 10) and with Barr for chlordiazepoxide/amitriptyline HCl (Dec. 10). Mylan's remaining first approvals in 1986 were for doxepin HCl, meclofenamate sodium, and tolazamide. Mylan had four first approvals in 1985.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth